Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel plus Oxaliplatin as second-line therapy in advanced metastatic pancreatic cancer
2005-004236-40Phase 2Completed
- Sponsor
- University Hospital Ulm
- Start
- Oct 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and oxaliplatin in pancreatic adenocarcinoma (PDAC), sponsored by University Hospital Ulm. Primary endpoint: Tumor response. Started Oct 2007; status: completed.
02
Drugs
docetaxeloxaliplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2005-004236-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004236-40.